Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 23

Results For "inhibitor"

386 News Found

Aurigene reports results of AUR101 in phase II study in US patients
News | December 19, 2022

Aurigene reports results of AUR101 in phase II study in US patients

AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients


Torrent enters into co-marketing partnership with Boehringer Ingelheim India
News | December 15, 2022

Torrent enters into co-marketing partnership with Boehringer Ingelheim India

Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.


Takeda launches CINRYZE in India for hereditary angioedema patients
News | December 15, 2022

Takeda launches CINRYZE in India for hereditary angioedema patients

CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.


Biocon initiates clinical study of Itolizumab for ulcerative colitis in India
Diagnostic Center | December 15, 2022

Biocon initiates clinical study of Itolizumab for ulcerative colitis in India

This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study


LG Chem inks deal with Innovent Biologics for gout treatment candidate
News | December 15, 2022

LG Chem inks deal with Innovent Biologics for gout treatment candidate

LG Chem will receive totaling up to $95.5 million for the China rights


GSK’s new data underscore important responses with momelotinib for myelofibrosis patients
Diagnostic Center | December 12, 2022

GSK’s new data underscore important responses with momelotinib for myelofibrosis patients

48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response


Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study
News | December 05, 2022

Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study

Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer


Merck to present data from Its hematology portfolio ASH meeting
News | December 05, 2022

Merck to present data from Its hematology portfolio ASH meeting

Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers


EMA accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis
News | December 05, 2022

EMA accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis

Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints


JB Pharma gets USFDA approval for its generic Venlafaxine Extended-Release Tablets
Drug Approval | December 01, 2022

JB Pharma gets USFDA approval for its generic Venlafaxine Extended-Release Tablets

This product is based on Osmotic Controlled Release Oral Delivery System technology